Skip to main content
. 2017 May 23;8(25):39963–39977. doi: 10.18632/oncotarget.18102

Figure 6. PR5-LL-CM01 displayed significant anti-tumor effect in vivo.

Figure 6

A. No significant changes in body weight were observed over the course of treatment in either PANC1 or HT29 model after treatment with 20mg/kg of PR5-LL-CM01. (*P < 0.05, n = 4). B. Tumor efficacy study for PANC1 or HT29 cells which were subcutaneously implanted in NSG mice. Inhibition of tumor growth was observed upon treatment with 20mg/kg of PR5-LL-CM01 intraperitoneally for 3X/week, as compared to the vehicle control. (*P < 0.05, n = 4).